Terminated PHASE2 INTERVENTIONAL 2-arm NCT01060254

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions Cystitis Cystitis, Interstitial Urinary Bladder Diseases Urologic Diseases

Interventions JNJ-42160443 Placebo

Updated 9 times since 2017 Last updated: Oct 15, 2021 Started: Apr 6, 2010 Primary completion: Jun 24, 2011 Completion: Jun 24, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Logistic reasons associated with the FDA-imposed clinical hold.

Other terminated trials from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

More terminations from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

This PHASE2 trial investigates Cystitis and Cystitis, Interstitial and is currently terminated or withdrawn. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. leads this study, which shows 9 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE2
Nov 2021 — Apr 2022 [monthly]

Terminated PHASE2
Jan 2021 — Nov 2021 [monthly]

Terminated PHASE2

▶ Show 4 earlier versions

Dec 2019 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Dec 2019 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Data source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arlington, United States , Aventura, United States , Barrie, Canada , Birmingham, United States , Brighton, United States , Eagle, United States , Englewood, United States , Fair Oaks Ranch, United States , Glendora, United States , Greensboro, United States and 15 more locations